Tag Archives: NY-ESO-1

Thoughts on GSK’s Decision to Terminate its Collaboration with Immatics

On Thursday, November 17, Immatics held its Q3 2022 earnings call (press release / presentation) disclosing GSK’s decision to terminate their collaboration to develop novel adoptive cell therapies. Below, Celltelligence provides insights on how GSK’s decision to deprioritize its cell therapy programs could affect Immatics’s strategy, while discussing how BMS could benefit from it.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Afami-cel’s Rolling BLA Submission to Initiate in Q4 2022; Adaptimmune Prioritizes MAGE-A4 and PRAME Assets; No Major Updates for Gavo-cel and TC-510; Adaptimmune and TCR2 Tx Q3 2022 Earnings Summaries

On Tuesday, November 8, 2022, Adaptimmune held its Q3 2022 earning call (press release) highlighting that afami-cel’s (MAGE-A4 SPEAR-T) rolling BLA submission for synovial sarcoma will initiate in Q4 2022. Additionally, management announced that they will focus exclusively on MAGE-A4 and PRAME assets, while deprioritizing or pausing the development of non-core programs. On the same day, TCR2 Tx reported its Q3 2022 financials and business updates (press release) highlighting positive topline results from gavo-cel’s (TC-210; autologous mesothelin TRuC-T) Ph1/2 trial in mesothelin-expressing solid tumors. Below, Celltelligence provides insights on Adaptimmune’s pipeline prioritization strategy after GSK’s transfer of assets, while discussing potential delays in TCR2 Tx’s programs.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

GSK Deprioritizes Cell Therapy Franchise; GSK’s Q3 2022 Earnings Summary

On Wednesday, November 2, GSK held its Q3 2022 earnings call (press release / presentation), highlighting the removal of three clinical TCR-T programs from its pipeline. Below, Celltelligence provides insights on GSK’s pipeline update, while discussing the company’s future in cell therapy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on GSK’s Decision to Transfer Cell Therapy Programs to Adaptimmune and Terminate Collaboration with Lyell; Is GSK Giving Up on Cell Therapy?

On Tuesday, October 25, Adaptimmune announced (press release / SEC Form 8-K) the transfer of GSK’s NY-ESO and PRAME cell therapy programs to Adaptimmune. Additionally, on Monday, October 24, Lyell Immunopharma reported (SEC Form 8-K) that GSK has terminated its agreement with Lyell for the research and development of T-cell therapies, including LYL132 and LYL331. Below, Celltelligence provides insights on how GSK’s decision could affect the strategy from Adaptimmune and Lyell, while discussing GSK’s uncertain future in cell therapy.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Updated Guidance for Lete-cel; GSK / Haleon Business Separation Completed; GSK’s Q2 2022 Earnings Call Summary

On Wednesday, July 27, GSK held their Q2 2022 earnings call (presentation / press release) providing updated guidance for their lead cell therapy asset lete-cel (NY-ESO-1 TCR-T) and confirming the successful separation of the consumer healthcare business (Haleon). Below, Celltelligence provides insights on lete-cel’s potential approval while comparing with key competitor afami-cel (Adaptimmune’s MAGE-A4 SPEAR-T).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

BMS’s Breyanzi and Abecma Sales Increase; Could Abecma’s Continued Viral Vector Shortage Favor Cilta-cel’s Upcoming Launch? No Updates on GSK’s Cell Therapy Assets; BMS and GSK Q3 2021 Earnings Call Summaries

On Wednesday, October 27, BMS held their Q3 2021 earnings presentation (press release / presentation) highlighting Breyanzi’s (CD19 CAR-T) and Abecma’s (BCMA CAR-T) continued revenue growth. Furthermore, management commented that Abecma’s vector supply issues may not be fully resolved before H2 2022. On the same day, GSK presented their Q3 2021 financial results (press release / presentation). However, the company did not provide any updates on their cell therapy assets in development.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

GSK Explores Better Patient Selection Methods for Lete-cel; Could 2seventy bio Nominate Medigene’s PRAME TCR-T as Their Second Target? Adaptimmune Presents Preclinical Data from ADP-A2M4CD8; No Updated Preclinical Results from Carisma; Tecartus Absent from CHMP Highlights; ESMO 2021 Day 1&2

On the first two days of ESMO 2021, four key pre-clinical and clinical presentations from GSK, Medigene, Adaptimmune, and Carisma were presented. On Friday, September 17, the CHMP highlights for September were released. Of note, no updates from Tecartus’s Type II variation for r/r adult ALL were observed. Below, Celltelligence provides insights and context for each presentation, while providing likely EU approval timelines for Tecartus.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

GSK and Adaptimmune Present TCR-T Data for Lete-cel and Afami-cel; Novel CAR-Ts for Solid Tumors From Minerva and OriginCell; Will Remodeling the TME With CAR-Ts Improve Solid Tumor Therapies? ASCO 2021 Day 3 Part I

On the third day of ASCO 2021, seven key solid tumor related updates were presented from GSK, Adaptimmune, Minerva, OriginCell Therapeutics, Baylor College / NCI, and UPenn. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.